<DOC>
	<DOCNO>NCT02432378</DOCNO>
	<brief_summary>The main goal research study determine intraperitoneal ( IP ) administration cisplatin addition investigational vaccine ( DC vaccine ) without investigational drug combination IP rintatolimod , IP interferon alpha-2b ( IFN ) , oral celecoxib , effect , good bad , recurrent ovarian cancer .</brief_summary>
	<brief_title>Intensive Locoregional Chemoimmunotherapy Recurrent Ovarian Cancer Plus Intranodal DC Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Patients must peritoneal recurrence epithelial adenocarcinoma carcinosarcoma ovarian , tubal , peritoneal origin . Histologic documentation original primary tumor require via pathology report . Original tumor block primary diagnosis review study pathologist Magee . Patients must complete frontline taxane/platinumbased therapy primary tumor progression free interval great 6 month last therapy measurable relapsed disease must present abdomen great 1 cm . Patients must documentation defined initial progression free interval ( PFI 1 ) great 6 month follow frontline therapy . Patients must documentation relapse include either double CA125 serum level confirm measurement great one week apart identification new measurable lesion great 1 cm peritoneal cavity either CT/MRI , PET/CT scan physical exam ( expand pocket ascites fluid may serve alternative source tumor cell ) index lesion accessible biopsy vaccine formulation . Recurrence outside peritoneal cavity access use standard RECIST criterion . Patients must reasonable candidate laparoscopy IP platinum regimen prior evidence clinically significant intraabdominal adhesion , persistent abdominal wall infection , renal toxicity , bowel obstruction . Prior enrollment , CA125 elevate least double level see nadir value follow first complete response measurable intraperitoneal disease identify radiologically accessed laparoscopy/laparotomy biopsy peritoneal catheter placement . Patients must document available tumor great 1 cm bulk tumor mass 200 cc ascites fluid tumor isolation prior start chemotherapy . Patients childbearing potential must negative pregnancy test prior study entry practice effective form contraception . If applicable , patient must discontinue breastfeed prior first date treatment study . Patient may require undergo leukapheresis ( depend study phase/cohort ) must agree leukapheresis assign . Patients must agree appropriate clinical monitoring receive study regimen . Bone marrow function : Absolute neutrophil count ( ANC ) great equal 1,500/µL , equivalent CTCAE v4 grade 1 . Platelets great equal 100,000/µL ; hemoglobin great equal 8.0 g/dL . Renal function : creatinine le equal 1.5 x institutional upper limit normal ( ULN ) , CTCAE v4 grade 1 . Hepatic function : Bilirubin le equal 1.5 x ULN ( CTCAE v4 grade 1 ) . SGOT alkaline phosphatase less equal 2.5 x ULN ( CTCAE v4 grade 1 ) . Patients sign informed consent authorization permit release personal health information . Patients must ≥ 18 year age . Patients must GOG Performance Status 0 1 . Patients active autoimmune disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus ( SLE ) , ulcerative colitis , Crohn 's Disease , multiple sclerosis ( MS ) , ankylose spondylitis ) . Patients know allergy cisplatin chemotherapy . Patients carboplatin allergy may include tolerate test dose IV cisplatin give monitor floor condition . Patients chronically treat immunosuppressive drug cyclosporin , adrenocorticotropic hormone ( ACTH ) , systemic corticosteroid . Patients recognize immunodeficiency disease include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia ; patient acquire , hereditary , congenital immunodeficiency . Patients uncontrolled disease cancer exclude . Patients pregnant nursing . Patients contraindication use NSAID 's like chronic renal failure , coronary artery disease , bleed ulcer . Patients tumor low malignant potential , except ovarian pseudomyxoma peritoneal disease . Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence malignancy present within last five year . Patients also exclude previous cancer treatment contraindicate protocol therapy . Patients previous pelvic radiation therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>